Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/2041
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMedrano, Luz María-
dc.contributor.authorTaxonera, Carlos-
dc.contributor.authorGonzález-Artacho, Cristina-
dc.contributor.authorPascual, Virginia-
dc.contributor.authorGómez-García, María-
dc.contributor.authorBarreiro-de Acosta, Manuel-
dc.contributor.authorPérez-Calle, José L-
dc.contributor.authorBermejo, Fernando-
dc.contributor.authorLópez-Sanromán, Antonio-
dc.contributor.authorMartín Arranz, Dolores-
dc.contributor.authorGisbert, Javier P-
dc.contributor.authorMendoza, Juan Luis-
dc.contributor.authorMartín, Javier-
dc.contributor.authorNúñez, Concepción-
dc.contributor.authorUrcelay, Elena-
dc.date.accessioned2015-10-27T12:30:42Z-
dc.date.available2015-10-27T12:30:42Z-
dc.date.issued2015-
dc.identifier.citationMedrano LM, Taxonera C, González-Artacho C, Pascual V, Gómez-García M, Barreiro-de Acosta M, et al. Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile. Mediators Inflamm.; 2015:318207es
dc.identifier.issn1466-1861 (Online)-
dc.identifier.issn0962-9351 (Print)-
dc.identifier.otherPMC4539178-
dc.identifier.urihttp://hdl.handle.net/10668/2041-
dc.descriptionJournal Article; Research Support, Non-U.S. Gov't;es
dc.description.abstractSubstantial proportion of Crohn's disease (CD) patients shows no response or a limited response to treatment with infliximab (IFX) and to identify biomarkers of response would be of great clinical and economic benefit. The expression profile of five genes (S100A8-S100A9, G0S2, TNFAIP6, and IL11) reportedly predicted response to IFX and we aimed at investigating their etiologic role through genetic association analysis. Patients with active CD (350) who received at least three induction doses of IFX were included and classified according to IFX response. A tagging strategy was used to select genetic polymorphisms that cover the variability present in the chromosomal regions encoding the identified genes with altered expression. Following genotyping, differences between responders and nonresponders to IFX were observed in haplotypes of the studied regions: S100A8-S100A9 (rs11205276* G/rs3014866* C/rs724781* C/rs3006488* A; P = 0.05); G0S2 (rs4844486* A/rs1473683* T; P = 0.15); TNFAIP6 (rs11677200* C/rs2342910* A/rs3755480* G/rs10432475* A; P = 0.10); and IL11 (rs1126760* C/rs1042506* G; P = 0.07). These differences were amplified in patients with colonic and ileocolonic location for all but the TNFAIP6 haplotype, which evidenced significant difference in ileal CD patients. Our results support the role of the reported expression signature as predictive of anti-TNF outcome in CD patients and suggest an etiological role of those top-five genes in the IFX response pathway.es
dc.description.sponsorshipFinancial support for the study was provided by Fundación Mutua Madrileña.es
dc.language.isoenes
dc.publisherHindawi Publishing Corporationes
dc.relation.ispartofMediators of inflammationes
dc.subjectAnticuerpos monoclonaleses
dc.subjectMarcadores biológicoses
dc.subjectEnfermedad de Crohnes
dc.subjectGenotipoes
dc.subjectHaplotiposes
dc.subjectHumanoses
dc.subjectÍleones
dc.subjectColones
dc.subjectInterleucina-11es
dc.subjectPolimorfismo genéticoes
dc.subjectFactor de necrosis tumoral alfaes
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonales
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Biological Factors::Biological Markerses
dc.subject.meshMedical Subject Headings::Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases::Crohn Diseasees
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genotypees
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genotype::Haplotypeses
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses
dc.subject.meshMedical Subject Headings::Anatomy::Digestive System::Gastrointestinal Tract::Intestines::Intestine, Small::Ileumes
dc.subject.meshMedical Subject Headings::Anatomy::Digestive System::Gastrointestinal Tract::Intestines::Intestine, Large::Colones
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines::Interleukins::Interleukin-11es
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetices
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Intercellular Signaling Peptides and Proteins::Tumor Necrosis Factors::Tumor Necrosis Factor-alphaes
dc.titleResponse to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile.es
dc.typeinfo:eu-repo/semantics/articlees
dc.description.versionYeses
dc.identifier.pmid26339133-
dc.rights.accessRightsAcceso abiertoes
dc.identifier.doi10.1155/2015/318207-
dc.type.versioninfo:eu-repo/semantics/publishedes
dc.relation.publisherversionhttp://www.hindawi.com/journals/mi/2015/318207/abs/es
dc.contributor.authoraffiliation[Medrano,LM; Pascual,V; Núñez,C; Urcelay,E] Immunology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [Taxonera,C; Mendoza,JL] Gastroenterology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [González-Artacho,C; Gómez-García,M] Gastroenterology Department, Virgen de las Nieves Hospital, Granada, Spain. [Barreiro-de Acosta,M] Gastroenterology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain. [Perez-Calle,JL] Gastroenterology Department, Alcorcón Hospital, Madrid, Spain. [Bermejo,F] Gastroenterology Department, Fuenlabrada Hospital, Madrid, Spain. [López-Sanromán,A] Gastroenterology Department, Fuenlabrada Hospital, Madrid, Spain. [Martín Arranz,D] Gastroenterology Department, La Paz Hospital, Madrid, Spain. [Gisber,JP] Gastroenterology Department, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. [Martín,J] Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla, Granada, Spain.es
dc.type.subtypeArtículoes
Appears in Collections:01- Artículos - Hospital Virgen de las Nieves

Files in This Item:
File Description SizeFormat 
Medrano_ResponseToInfliximab.pdfArtículo publicado1,32 MBAdobe PDFView/Open


This item is protected by original copyright



This item is licensed under a Creative Commons License Creative Commons